ALDX News and Press, Aldeyra Therapeutics Inc. From 06/27/23

Relative to Placebo, Statistical Significance Achieved for Reduction in Awake Cough Frequency (P=0.01), 24‑Hour Cough Frequency (P=0.001), Awake Cough Count (P=0.001), and 24‑Hour Cough Count (P=0.001) ADX-629 Was Well Tolerated and No Safety Concerns Were Identified ...

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced it will host a webcast and conference call on Tuesday, June 27, 2023, at 8:00 a.m. (ET) to provide top-line results from the Phase 2 clinical trial of ADX‑629 in patients with chronic cough. The dial-in numbers are (...

2023-06-23 07:06:25 ET Aldeyra Therapeutics ( NASDAQ: ALDX ) to be added to the Russell 2000 and the Russell 3000 indexes, effective after the U.S. equity markets close on June 23, 2023. Source: Press Release For further details see: Aldeyra Therapeutics to join ...

(Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that it will be added to the Russell 2000® and the Russell 3000® indexes, effective after the U.S. equity markets clos...

2023-06-21 13:20:27 ET Gainers: Argo Blockchain ( ARBK ) +32% . Ocean Biomedical ( OCEA ) +21% . Mullen Automotive ( MULN ) +20% . Freightos Limited ( CRGO ) +18% . PureCycle Technologies ( PCT ) +17% . PetVivo Holdings ( P...

2023-06-21 10:29:37 ET Aldeyra Therapeutics ( NASDAQ: ALDX ) fell ~21% in the morning hours Wednesday after announcing that the U.S. FDA declined to approve its marketing application for ADX-2191, an investigational therapy for primary vitreoretinal lymphoma (PVRL). In its...

Based on U.S. Food & Drug Administration (FDA) Determination of Lack of Adequate and Well Controlled Investigations in the Scientific Literature, Complete Response Letter Received for New Drug Application (NDA) of ADX-2191 (methotrexate injection, USP) for the Treatment of Primary Vitreoretin...

2023-06-16 10:55:29 ET Summary Aldeyra Therapeutics reported positive results from a Phase III study of Reproxalap, an eye drop drug for allergic conjunctivitis and dry eye disease that provides immediate relief to patients. The trial results showed statistically significant impro...

2023-06-15 10:06:53 ET Gainers: Aldeyra Therapeutics ( ALDX ) +11% . Bioventus ( BVS ) +11% . IO Biotech ( IOBT ) +11% . Verastem ( VSTM ) +10% . Zentalis Pharmaceuticals ( ZNTL ) +9% . Losers: Mersana Therapeutics ( MRSN...

Statistical Significance Achieved for Primary Endpoint of Ocular Itching at All Prespecified Timepoints (P<0.0001) Statistical Significance Achieved for Key Secondary Endpoint of Ocular Redness (P=0.004) Statistical Significance Achieved for Secondary Endpoints of Ocular Tearin...